YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 26.2%
Concerns1
- Operating margin declining for 3 consecutive years (32.0% β 30.0% β 29.0%)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 9 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ442.00 Cr | β | βΉ88.00 Cr | β | β | 5.8% | 12.2% | 4.8% |
| Mar 2024 | βΉ394.00 Cr | β | βΉ84.00 Cr | β | β | 10.0% | 19.0% | 31.3% |
| Mar 2023 | βΉ331.00 Cr | β | βΉ64.00 Cr | β | β | 36.2% | 19.1% | 52.4% |
| Mar 2022 | βΉ278.00 Cr | β | βΉ42.00 Cr | β | β | 37.5% | 68.5% | 250.0% |
| Mar 2021 | βΉ165.00 Cr | β | βΉ12.00 Cr | β | β | 17.4% | 34.1% | 1100.0% |
| Mar 2020 | βΉ123.00 Cr | β | βΉ1.00 Cr | β | β | 1.8% | 35.2% | -66.7% |
| Mar 2019 | βΉ91.00 Cr | β | βΉ3.00 Cr | β | β | 5.5% | 16.7% | -50.0% |
| Mar 2018 | βΉ78.00 Cr | β | βΉ6.00 Cr | β | β | 12.5% | 9.9% | 100.0% |
| Mar 2017 | βΉ71.00 Cr | β | βΉ3.00 Cr | β | β | 7.9% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 490 |
| Total Expenses | 364 |
| EBIT / Operating Profit | 126 |
| OPM % | 26% |
| Other Income | 21 |
| Finance Costs | 1 |
| Depreciation & Amortisation | 21 |
| Profit Before Tax | 125 |
| Tax % | - |
| Net Profit / PAT | 92 |
| EPS (βΉ) | 9.53 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITEDthis co. | βΉ6.19 K Cr | βΉ442.00 Cr | 67.30 | 3.93 | 45.53 | 12.2% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |